Effect of metformin therapy on anti-Mullerian hormone (AMH) level in women with infertility and polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201403132967N5

Enrollment

Registered

2015-01-12

Start date

2014-05-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Tab metformine 1500mg, daily , PO -Two months.

Treatment - Drugs

Tab metformine 1500mg, daily , PO -Two months

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: inclusion criteria : pationt with infertility and polycystic ovary syndrome the PCOS was mead according to roterdome criteria exclusion criteria :metformin use contraindication; metformin use during 4 months before study; use of OCP during 2 months before study; thyroid function disorder; hyper prolactinemia; diabetes melituse; cogenital adrenal hyperplasia; Use of drugs affect on adrenal and ovarian function and metabolism of carbohydrates and lipids

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum anti-Mullerian hormone levels. Timepoint: Before the intervention and Two months after intervention. Method of measurement: Laboratory Kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Fatemeh Foroozanfard

Kashan university Of Medical sciences

forozanfar_f@kaums.ac.ir; fatemehforoozanfard@yahoo.com+98 31 5542 1355

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026